1. 2930 Relationship between MRI caracteristics and plasmatic baseline levels of MMP2 and MMP9 in patients with recurrent high-gade gliomas treated with bevacizumab. (September 2015) Authors: Farina, P.; Tabouret, E.; Lehmann, P.; Barrie, M.; Petrirena, G.; Campello, C.; Boucard, C.; Girard, N.; Chinot, O. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO‐RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END‐POINT OF THE ILOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK. (June 2017) Authors: Soussain, C.; Choquet, S.; Houillier, C.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; Nicolas‐Virelizier, E.; Barrie, M.; Moluçon‐Chabrot, C.; Lelez, M.; Clavert, A.; Coisy, S.; de la Bretonnière, M. Ertault; El Yamani, A.; Touitou, V.; Cassoux, N.; Boussetta, S.; Broussais, F.; Gelas‐Dore, B. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. (August 2019) Authors: Soussain, C.; Choquet, S.; Blonski, M.; Leclercq, D.; Houillier, C.; Rezai, K.; Bijou, F.; Houot, R.; Boyle, E.; Gressin, R.; Nicolas-Virelizier, E.; Barrie, M.; Moluçon-Chabrot, C.; Lelez, M.L.; Clavert, A.; Coisy, S.; Leruez, S.; Touitou, V.; Cassoux, N.; Daniau, M. Journal: European journal of cancer Issue: Volume 117(2019) Page Start: 121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗